Osteocyte deficiency in hip fractures

Calcified Tissue International

Volumn 89, Issue 4, 2011, Pages 327-334

  Delgado Calle, Jesús ^a   Arozamena, Jana ^a   García Renedo, Raúl ^b   García Ibarbia, Carmen ^a   Pascual Carra, María A ^b   González Macías, Jesús ^a   Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

FGF23; Osteocytes; Osteoporosis; PHEX; Sclerostin

Indexed keywords

CASPASE 3; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; SCLEROSTIN; WNT PROTEIN;

AGED; APOPTOSIS; ARTICLE; BONE BIOPSY; CONTROLLED STUDY; FEMALE; FEMUR HEAD; FGF23 GENE; GENE; GENE EXPRESSION; HIP FRACTURE; HIP OSTEOARTHRITIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOCYTE; OSTEOCYTE DEFICIENCY; PHEX GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA TRANSCRIPTION; SOST GENE; TRABECULAR BONE;

AGED; AGED, 80 AND OVER; BLOOD PROTEINS; BONE AND BONES; CELL COUNT; COHORT STUDIES; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HIP FRACTURES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OSTEOCYTES; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEINS;

EID: 82755160854     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-011-9522-0     Document Type: Article

References (40)

1. Komatsu DE, Mary MN, Schroeder RJ, Robling AG, Turner CH, Warden SJ (2010) Modulation of Wnt signaling influences fracture repair. J Orthop Res 28:928-936
2. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99-107
3. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140 (Pubitemid 41397109)
4. Johnson ML, Harnish K, Nusse R, Van Hul W (2004) LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 19: 1749-1757 (Pubitemid 41103424)
5. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229-238
6. Rochefort GY, Pallu S, Benhamou CL (2010) Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 21:1457-1469
7. Dallas SL, Bonewald LF (2010) Dynamics of the transition from osteoblast to osteocyte. Ann NY Acad Sci 1192:437-443
8. Velasco J, Zarrabeitia MT, Prieto JR, Perez-Castrillon JL, Perez- AguilarMD, Perez-NunezMI, Sanudo C,Hernandez-Elena J,Calvo I, Ortiz F, Gonzalez-Macias J, Riancho JA (2010) Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int 21:109-118
9. Hernandez JL, Garcés CM, Sumillera M, Fernandez-Aldasoro EV, Garcia-Ibarbia C, Ortiz JA, Arozamena J, Alonso MA, Riancho JA (2008) Aromatase expression in osteoarthritic and osteoporotic bone. Arthritis Rheum 58:1696-1700 (Pubitemid 351847522)
10. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887 (Pubitemid 41379516)
11. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844 (Pubitemid 41598769)
12. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wntmediated bone formation. J Biol Chem 284:10890-10900
13. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935 (Pubitemid 40994212)
14. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
15. Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26
16. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB (2009) Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 24:597-605
17. Verborgt O, Gibson GJ, Schaffler MB (2000) Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 15:60-67 (Pubitemid 30026933)
18. Clark WD, Smith EL, Linn KA, Paul-Murphy JR, Muir P, Cook ME (2005) Osteocyte apoptosis and osteoclast presence in chicken radii 0-4 days following osteotomy. Calcif Tissue Int 77:327-336 (Pubitemid 41704911)
19. Power J, Parker M, Papapoulos S, Van Bezooijen R, Reeve J, Loveridge N (2011) Osteocytic sclerostin expression is locally reduced at the site of femoral neck fracture (abstract). Bone 48(suppl 2):S168
20. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464-475 (Pubitemid 46825494)
21. Watanabe K, Ikeda K (2010) Osteocytes in normal physiology and osteoporosis. Clin Rev Bone Miner Metab 8:224-232
22. Zarrinkalam MR, Mulaibrahimovic A, Atkins GJ, Moore RJ (2011) Changes in osteocyte density correspond with changes in osteoblast and osteoclast activity in an osteoporotic sheep model. Osteoporos Int [Epub ahead of print]
23. Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T (2008) Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 56:561-567 (Pubitemid 351702300)
24. Bellido T (2006) Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 6:358-359 (Pubitemid 46099716)
25. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957-1967 (Pubitemid 351229312)
26. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bonucci E (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269 (Pubitemid 47106897)
27. Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC (2009) Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 46:389-399
28. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283: 5866-5875
29. Gregson C, Poole K, Steel C, Ayuk J, McCloskey E, Fraser W, Tobias J (2011) Elevated sclerostin levels in individuals with high bone mass (abstract). Bone 48(suppl 2):S71-S72
30. Fisher A, Srikusalanukul W, Davis M, Smith P (2010) Hip fracture type: important role of parathyroid hormone (PTH) response to hypovitaminosis D. Bone 47:400-407
31. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991-1997
32. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E (2011) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women - the six-month effect of risedronate and teriparatide. Osteoporos Int [Epub ahead of print]
33. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373-379
34. Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, Bellido T (2011) Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone [Epub ahead of print]
35. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882-F889
36. Power J, Poole KE, Van Bezooijen R, Doube M, Caballero-Alias AM, Lowik C, Papapoulos S, Reeve J, Loveridge N (2010) Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res 25: 1867-1876
37. Qiu S, Rao DS, Palnitkar S, Parfitt AM (2003) Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 18:1657-1663 (Pubitemid 37022924)
38. Qiu S, Rao DS, Palnitkar S, Parfitt AM (2006) Differences in osteocyte and lacunar density between black and white American women. Bone 38:130-135 (Pubitemid 43006083)
39. Patsch JM, Kohler T, Berzlanovich A, Muschitz C, Bieglmayr C, Roschger P, Resch H, Pietschmann P (2011) Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res 26: 1584-1592
40. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257-3262